UNSPSC 51384526: Ibuprofen lysinate

This classification denotes a cyclooxygenase inhibitor with the molecular formula C13H18O2.C6H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N01ORX9D6S, chemically known as l-lysine, .alpha.-methyl-4-(2-methylpropyl)benzeneacetate (1:1), but more generally known as ibuprofen lysinate, which bears US NIH Compound Identifier 42368. European Medicines Agency schedules ibuprofen lysinate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08098MIG.

Most nations, for tariff purposes, schedule ibuprofen lysinate under HS 29163990. SMILES: CC(C)CC1CCC(CC1)C(C)C(=O)O.C(CCN)C[C@@H](C(=O)O)N.

UNSPSC 51384526 Ibuprofen lysinate is a Commodity code, but recent state and local solicitations tagged under it do not reflect ibuprofen lysinate procurement — instead, they show purchasing activity across a broader pharmaceutical and medical countermeasure landscape. Seminole County, Florida is procuring naloxone and drug deactivation systems through competitive bidding; Texas HHS is conducting market intelligence on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is sourcing generic multi-source pharmaceuticals and over-the-counter products through authorized wholesalers. The mismatch between the code's nominal scope and the recent opportunities signals that this Commodity code sees little relevant recent activity for ibuprofen lysinate specifically, and the posted solicitations may reflect broader tagging or misclassification in the source data rather than true ibuprofen lysinate procurement.

Activity under this code spans state health and human services agencies, county public health departments, and cooperative purchasing alliances serving multiple state and local governments. The Minnesota Multistate Cooperative Purchasing Alliance represents the largest documented recent procurement, with an RFP posted January 20, 2026, and a proposal deadline of March 26, 2026, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson) with products effective July 1, 2026. Seminole County's IFB for naloxone and drug deactivation systems (posted June 30, 2026, with responses due July 26, 2023) and Texas HHS's RFI for direct-to-manufacturer prescriptions (April 3, 2026) reflect exploratory or narrow-scope procurement rather than broad ibuprofen lysinate demand. Geographic reach includes Minnesota, Texas, and Florida based on recent notices. Absent ibuprofen lysinate-specific solicitations, pursuit of this code should focus on monitoring for future pharmaceutical or OTC product RFPs under state cooperative purchasing vehicles and health agency direct-buy programs.